Ask My Investor AI
Public company · NYSEPublished company research
STVN

The FY2025 Form 20-F verifies Stevanato Group S.p.A., CIK 0001849853, Italian incorporation, euro reporting and NYSE ticker STVN.

Stevanato Group S.p.A.

Stevanato directly supplies drug-containment and delivery systems plus engineering equipment. Q1 2026 revenue was EUR273.6M, including EUR128.6M of High-Value Solutions revenue, while capacity investment continued at Fishers, Indiana and Latina, Italy. Essential-medicine-only economics and current valuation remain unresolved.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
STVN
Exchange
NYSE
HQ
Italy
Currency
EUR
SEC CIK
0001849853
Investment case

How this company captures the theme economics

Competitive position

Stevanato reports integrated drug-containment, delivery and engineering capabilities. Q1 2026 High-Value Solutions revenue was EUR128.6M, 47% of total revenue. The bounded evidence does not establish essential-medicine-only revenue, switching costs or current valuation.

Scarce assets

Regulated drug-containment manufacturing, sterile ready-to-use systems, delivery-device capability, inspection and assembly equipment, and recently expanded capacity at Fishers and Latina.

Products, segments, and customers

Biopharmaceutical and Diagnostic Solutions supplies vials, prefilled syringes, cartridges and delivery systems; Engineering supplies inspection, assembly and packaging equipment. Q1 2026 BDS revenue was EUR249.0M and total revenue was EUR273.6M.

Theme capture

Issuer evidence verifies direct containment and delivery capability, a 47% High-Value Solutions mix, GLP-1 exposure and capacity investment. It does not isolate essential-medicine revenue, orders or margins.

Conditions

What must be true

  1. Fishers and Latina capacity ramps must earn acceptable returns without creating sustained excess capacity.
  2. Containment and delivery demand must remain diversified enough that GLP-1 concentration does not overwhelm the broader essential-medicine signal.

Identifiable catalysts

  • Successful Fishers and Latina capacity ramp with improving utilization and cash conversion
  • Sustained growth in High-Value Solutions beyond GLP-1 demand
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Drug containment and delivery supplier (EZ-fill vials, prefilled syringes, cartridges) plus engineering

Essential medicine manufacturing resilience

Direct and financially material at the broad portfolio level: Q1 2026 total revenue was EUR273.6M, BDS revenue was EUR249.0M and High-Value Solutions revenue was EUR128.6M. Essential-medicine-specific revenue and margins are not isolated.

Evidence
The issuer's Q1 2026 release directly supports containment and delivery capability, revenue, high-value mix, GLP-1 exposure and capacity investment at Fishers and Latina. Essential-medicine-only economics are not disclosed.
Materiality
not assessed — BDS and High-Value Solutions revenue are disclosed and financially material, but essential-medicine-specific revenue, orders and margins are not isolated.
Financial evidence

Official public disclosures

Reference period: Q1 2026.

  • RevenueEUR273.6 million
    Q1 2026[2]
  • High-Value Solutions revenueEUR128.6 million (47% of total revenue)
    Q1 2026[2]
  • Biopharmaceutical and Diagnostic Solutions revenueEUR249.0 million
    Q1 2026[2]
  • Adjusted EBITDAEUR65.5 million
    Q1 2026[2]
  • Capital expendituresEUR67.6 million
    Q1 2026[2]

Limitation: The figures cover broad containment, delivery and engineering operations, not essential-medicine-specific economics. Current market-derived valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • GLP-1 represented about 21-22% of Q1 2026 revenue, creating concentration and demand-normalization risk.
  • Heavy capacity investment at Fishers and Latina can pressure cash flow or returns if utilization ramps slowly.
  • Quality or regulatory failures in drug-containment manufacturing could interrupt customer supply.

Thesis-break conditions

  • High-Value Solutions growth reverses over multiple periods while new capacity remains underutilized.
  • A material quality or regulatory event interrupts containment-system supply.
Investability conclusion

Where the evidence lands

Official filing and Q1 2026 evidence verify the issuer's identity, containment and delivery capability, high-value product mix and capacity investment. Essential-medicine-only economics, customer concentration, switching costs and licensed current valuation remain unresolved. No reviewer has accepted the subject; it remains NOT_READY.

Next diligence

  1. Model Fishers and Latina ramp economics and returns; track high-value mix, GLP-1 dependence and free cash flow.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Stevanato Group FY2025 Form 20-FU.S. Securities and Exchange Commission (EDGAR) · primary · published 2026-04-23 · accessed 2026-07-29
  2. Stevanato Group delivers 7% revenue growth, 10% at constant currency, in first quarter 2026Stevanato Group S.p.A. · primary · published 2026-05-07 · accessed 2026-07-29